ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Proteomic profiling of CD133 + and CD326 + (EpCAM) subpopulations in A549 cells: insights into pluripotency and tumor heterogeneity.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThis study aimed to isolate different cancer cell populations and characterize their secretome profiles to better understand their functional roles in metastasis and tumor progression. For this purpose, we analyzed the secretomes of CD133 and CD326 (EpCAM) positive subpopulations derived from the A549 cell line.
methodsCD133 positive (cancer stem cell marker) and CD326 positive (pluripotent stem cell marker) cells were isolated from the A549 non-small cell lung cancer cell line using magnetic cell separation. Secretome proteins from these subpopulations, along with parental A549 cells, were analyzed using bottom-up proteomics via liquid chromatography-tandem mass spectrometry (LC-MS/MS). The resulting datasets were further evaluated through bioinformatics analyses.
resultsCD133 positive cells were associated with angiogenesis, mesenchymal stem cell differentiation, and enhanced cell migration. In contrast, CD326 positive cells demonstrated pluripotent characteristics linked to epithelial-mesenchymal transition, neuronal differentiation, and placental morphogenesis, indicating a potential role in metastatic processes. Additionally, SERPINE2 and ADAM10 were identified as potential biomarkers for lung cancer, while YWHAZ and TRIM28 were associated with pluripotent cancer stem cell phenotypes.
conclusionThese findings support the existence of distinct cancer stem cell subtypes exhibiting multipotent and pluripotent properties. Secretome profiling provides valuable insights into tumor heterogeneity and highlights novel biomarker candidates, offering potential avenues for improved diagnosis and targeted therapeutic strategies in lung cancer.
Indexed as
Identifiers
41870841What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.